Choksi Laboratories Reports Strong YoY Profit Growth in Q1 FY27

Revenue at Rs 12.08 crore, PAT at Rs 0.58 crore.

Reader Takeaway: YoY profit surge contrasts with sequential decline; AGM and RTA change noted.

What just happened

Choksi Laboratories Ltd. announced its financial results for the first quarter of FY27 (ended June 30, 2026). The company reported revenue from operations of Rs 12.08 crore, a 7.4% increase compared to Rs 11.24 crore in Q1 FY26. Net profit after tax (PAT) saw a substantial rise of 51.3% year-on-year, reaching Rs 0.58 crore from Rs 0.39 crore in the same period last year.

Why this matters

The strong year-on-year profit growth indicates improved operational efficiency or better cost management. However, the sequential performance shows a decline, with revenue falling from Rs 12.82 crore in Q4 FY26 to Rs 12.08 crore in Q1 FY27, and net profit decreasing from Rs 1.03 crore to Rs 0.58 crore. This mixed performance warrants investor attention.

The backstory

Choksi Laboratories operates in the pharmaceuticals sector, focusing on manufacturing and trading of pharmaceutical products. The company has been working on expanding its product portfolio and market reach.

What changes now

The approval of Q1 FY27 results and the re-appointment of Ms. Himika Choksi as Whole Time Director for a five-year term provide continuity in management. The transition of the Registrar and Share Transfer Agent (RTA) to Ankit Consultancy is a procedural change that aims to streamline investor services.

The 33rd Annual General Meeting (AGM) is scheduled for September 18, 2026. During the AGM, shareholders will vote on key proposals, including the re-appointment of directors. The register of members and share transfer books will be closed from September 12 to September 18, 2026.

Risks to watch

Investors should monitor the sequential decline in revenue and profit, which could signal upcoming challenges in business momentum. The effectiveness of the new RTA and any potential impact on investor relations will also be key to watch.

Peer comparison

(No verifiable peer comparison data available in the filing.)

Context metrics (time-bound)

Q1 FY27 Revenue: Rs 12.08 crore (Standalone)
Q1 FY27 PAT: Rs 0.58 crore (Standalone)
Year-on-Year Revenue Growth: ~7.4%
Year-on-Year PAT Growth: ~51.3%
Sequential Revenue Decline: ~5.8%
Sequential PAT Decline: ~43.5%
AGM Date: September 18, 2026

What to track next

Investors should track the company's performance in the upcoming quarters to see if the sequential dip is a temporary setback or a continued trend. The outcomes of the AGM and any strategic decisions announced will also be important.